SourceOne Global Partners LLC, a leading provider of health and wellness solutions created through scientific research and innovative product development, has announced that the VESIsorb® colloidal droplet delivery system has been awarded another U.S. patent, thus adding to its robust global intellectual property (IP) portfolio of patents and patents-pending.
This new U.S. patent number # 8,158,134 is described as an “umbrella patent” for the extensive coverage of a broad range of important natural product ingredients including but not limited to: coenzyme Q10, QH ubiquinol, omega-3 EFAs, vitamin D3, resveratrol, curcumin, tocotrienols, citrus polymethoxylated flavones, eriocitrin (from citrus) and many more.
“The addition of this U.S. patent strengthens the security of our innovation platform and protects our many investments in clinical research. These include both science-backed ingredients and proprietary condition-specific formulations that utilize the VESIsorb colloidal droplet delivery system,” Jesse Lopez, founder and CEO of SourceOne Global Partners commented.
Multiple studies have demonstrated the benefits of the patented VESIsorb delivery system, an innovation of Vesifact, a life science and drug delivery pioneer of Baar, Switzerland a spin-off from the Swiss Federal Institute of Technology, Zurich (ETH Zurich).
The peer-reviewed journal, Alternative Therapies in Health and Medicine, published the results of a double-blind study comparing the bioavailability of CoQ10 with VESIsorb to that of other “bio-enhanced” CoQ10 formulations. In the study, entitled, “Relative Bioavailability Comparison of Different Coenzyme Q10 Formulations with a Novel Delivery System,” the relative bioavailability of a single oral dose of CoQ10 (CoQsource® exclusively from SourceOne) was assessed using the area under curve (AUC (0-10h)) where the value for CoQ10 with VESIsorb reached 30.62 µg/ml/10h; a far superior 622 percent higher bioavailability than the oil-based formula. Furthermore, CoQ10 with VESIsorbhas higher plasma concentration levels over time.
A pharmacokinetic pilot study (single oral dose, crossover) in humans comparing Ubiquinol-QH to the same ubiquinol-QH in the VESIsorb delivery system (CoQsource QH exclusively from SourceOne) demonstrated an increase of 696 percent in peak blood levels (cmax) of ubiquinol. The relative bioavailability calculated using the area under the curve (AUC0-24h) was also increased by 485 percent.
Another pharmacokinetic pilot study (single oral dose, crossover) comparing absorption and bioavailability of Omega Choice 90 concentrated EPA Omega-3 fish oil to the same Omega Choice 90 in a VESIsorb®formulation demonstrated an increase of 567 percent in peak blood levels (cmax) of EPA in the formula that utilized the VESIsorb colloidal droplet delivery system. The relative bioavailability calculated using the area under the curve (AUC0-12h) was also increased by 487 percent.
Marc Weder, CEO of Vesifact, explains, “This new US patent provides security as our growing pipeline of new VESIsorb formulations are being launched at a time when the marketplace is desperately in need of new clinically proven natural health and wellness solutions.”
Lopez comments, “Our brand partners benefit tremendously because their products formulated with VESIsorb are patent-protected bio-enhanced formulations. These formulations build stronger brand equity with consumers seeking natural products that deliver optimal absorption and bioavailability.”